Yesterday, the World Health Organization gave the virus a new name: COVID-19.
The total numbers far exceed the toll of the 2003 SARS outbreak
Meanwhile, WHO holds meeting on fast-tracking vaccines, treatments for novel virus
The FDA has accepted for review a supplemental New Drug Application (sNDA) for Recarbrio™ (imipenem, cilastatin, and relebactam; Merck), to treat adult patients with hospital-acquired and ventilator-associated bacterial pneumonia.
Trial to be conducted in the central Chinese city of Wuhan, the epicenter of the outbreak.
The FDA has approved Audenz (influenza A [H5N1] monovalent vaccine; Seqirus) for active immunization for the prevention of disease in patients 6 months of age and older at increased risk of exposure to the influenza A H5N1 virus subtype contained in the vaccine.
Most early cases, but fewer subsequent cases, were linked to Huanan Seafood Wholesale Market.
The first instance of person-to-person spread of the 2019 novel coronavirus (2019-nCov) has been confirmed in the US, according to the Centers for Disease Control and Prevention (CDC).
Want to read more?
Please login or register first to view this content.